

# MEDICAMENT

## MEDICAL MARIJUANA RESEARCH NEWSLETTER



SUMMER 2022

### WELCOME TO MEDICAMENT,

the Consortium for Medical Marijuana Clinical Outcomes Research's quarterly newsletter.

The Consortium, founded by the State of Florida, conducts, disseminates, and supports research on the use and effects of medical marijuana on patient outcomes.

*In the Summer 2022 issue of MEDICAMENT:*

- Announced: Research Grant Awards 2022
- Event Summary: CCORC 2022
- Clinical Core Updates - Medical Marijuana and Me (M3)
- Outreach Updates
- Get Involved in Research



Consortium for  
Medical Marijuana  
Clinical Outcomes Research

To learn more about the Consortium and our programs, visit us at [mmjoutcomes.org](http://mmjoutcomes.org).

### ANNOUNCED: RESEARCH GRANT AWARDS 2022

Consortium awards \$579,532 in funding to the 2022 Research Grant Awardees

In June 2022, the Consortium completed the grants review process for the fourth cycle of the Consortium Research Grants program.


The Consortium board made funding decisions based on reviewer scores from ad-hoc, out-of-state subject matter experts and responsiveness of the proposals to the mission and research priorities. Of the 15 proposed research studies, 8 were selected for funding. This year the Consortium introduced two funding levels. Six of the awarded proposals, with a one-year research plan, were awarded level 1 funding. Two of the awarded proposals, with a two-year research plan and a clinical focus, were awarded for year 1 of a two-year funding plan (second year funding dependent upon continued state support and board review of progress toward year 1 goals).

The awarded research projects are from faculty belonging to 4 of the Consortium member institutions, including Florida State University, University of Central Florida, University of Florida, and University of Miami.

Funded research proposals include 5 with a clinical focus, 2 with a translational focus and one focused both on both clinical and translational outcomes. Research proposed involves studying patterns of CBD use in young adults with Crohn's disease; clinical outcomes of medical cannabis use in older adults; assessment of drug-drug interactions involving medical cannabis; consequences of THC-oxycodone polysubstance use; evaluation of immunomodulatory effects of chronic medical marijuana use

in HIV patients; effectiveness of CBD in pain control in postoperative eye surgery, and in those with spinal cord injury, as well as safety and efficacy of perinatal CBD use.

## 2022 GRANTS PROGRAM AWARDEES



PI: Naeen Chaudhry, MD  
University of Florida

**Cannabinoid Use in Young Adults with Crohn's Disease**



PI: Varan Govind  
University of Miami  
**Evaluation of Immunomodulatory Effects of Chronic Medicinal Marijuana Use and its Routes of Administration (Smoking Versus Vaping) on the Cerebral Metabolism, Morphology, Dopamine (via Neuromelanin MRI), and Neural Circuits of the Whole-Brain, and Pain in Young Adults Living with- and without-HIV\***




PI: Rodrigo Cristofolletti PhD  
University of Florida

**Quantitative Assessment of Complex Drug-Drug Interaction Networks Involving Medical Cannabis Products in Special Populations**



PI: Lori Knackstedt  
University of Florida

**A Translational Animal Model to Study Neurobehavioral Consequences of THC and Oxycodone Polysubstance Use**



PI: Robert Dvorak  
University of Central Florida

**Event-Level Changes in Psychiatric and Physical Symptoms Following Medicinal Cannabis Use in Older Adults**



PI: Walter Steigleman  
University of Florida

**Randomized, Controlled Cross-Over Comparison of Cannabidiol to Oral Opioid for Postoperative Photorefractive Keratectomy Pain Control**



PI: Debra Fadool  
Florida State University

**Long-Term Molecular, Metabolic and Behavioral Consequences of Perinatal Exposure to Cannabidiol (CBD) - A Safety and Efficacy Study**



PI: Eva Widerstrom-Noga  
University of Miami

**Effects of Cannabidiol on Resting State EEG and Neuropathic Pain Severity in People with Spinal Cord Injury\***

*Note: \* indicates a proposal awarded Level 2 funding*

**READ MORE ABOUT THE  
2022 GRANTS PROGRAM**

# CANNABIS CLINICAL OUTCOMES RESEARCH CONFERENCE (CCORC) HOSTS SECOND ANNUAL MEETING IN ORLANDO

CCORC 2022 attracts more than 125 participants



## CANNABIS CLINICAL OUTCOMES RESEARCH CONFERENCE 2023

MORE INFO TBA

*Learn, Share, and Advance Medical Marijuana Research*

MORE INFORMATION AT [CCORC.MMJOUTCOMES.ORG](https://ccorc.mmjoutcomes.org)



On Thursday, May 19th and Friday, May 20th, 2022, the Consortium for Medical Marijuana Clinical Outcomes Research hosted its second annual research conference, Cannabis Clinical Outcomes Research Conference (CCORC) in person and with virtual options, at the UF Research and Academic Center at Lake Nona, Orlando, FL.

Held in a hybrid format, CCORC 2022 attracted more than 125 attendees. The conference's program included three keynote speakers, panel discussions, workshops, a poster session for abstracts selected following peer review, and six oral presentations of top abstracts.

CCORC 2022 connected researchers, physicians, community stakeholders, and industry leaders fulfilling the following objectives: 1) disseminating research findings investigating medical cannabis use, efficacy, safety, and other relevant outcomes, 2) providing a venue for clinical and research educational opportunities related to medical cannabis, 3) fostering research collaboration and stakeholder engagement between Consortium member institutions and beyond.

Three main themes on clinical cannabis research conduct and interpretation emerged throughout the conference: 1) disentangling research findings comparing medical and non-medical cannabis use, 2) addressing barriers and promoting facilitators for conducting clinical cannabis research, and 3) resolving uncertainties around cannabis dosing.

The third annual CCORC is planned for summer 2023, official date TBA.

Click below to see photos from CCORC 2022, the full conference program, and a digital archive of research posters selected for CCORC 2022.

[VISIT THE CCORC WEBSITE](https://ccorc.mmjoutcomes.org)

---

## CCORC 2022 Keynote Speakers



### Staci Gruber, Ph.D.

**Director**, Cognitive and Clinical Neuroimaging Core, McLean Hospital

**Director**, Marijuana Investigations for Neuroscience Discovery (MIND), McLean Hospital

**Associate Professor of Psychiatry**, Harvard Medical School

**Clarifying Cannabis: Considering the Impact of Recreational and Medical Use on Cognitive and Clinical Outcomes**



### Kent Hutchison, Ph.D.

**Professor of Psychiatry**, Anschutz Medical Campus

**Adjunct Professor of Psychology and Neuroscience**, University of Colorado in Boulder

**Effects of THC and CBD: Implications for Future Clinical Trials**



### Samer Narouze, M.D., Ph.D.

**Associate Professor of Surgery**, Northeast Ohio Medical University

**Adjunct Professor of Psychology and Neuroscience**, University of Colorado in Boulder

**Effects of THC and CBD: Implications for Future Clinical Trials**

## CCORC 2022 Top Scoring Student Abstracts



### Erin Berthold

**Ph.D. Candidate**, Department of Pharmaceutics, University of Florida

**Preclinical Herb-Herb Interaction of Cannabidiol and Kratom in Rats**



### Alexandra McMahon, MPH

Department of Epidemiology, University of Florida

**Perceived Effectiveness of Medical Marijuana Among Adults with Chronic Pain: Findings from Interview Data in a Three-Month Pilot Study**



### Alexis Noel Cox, B.Sc.

**Undergraduate Scholar**, Department of Biological Science and Program in Neuroscience, Florida State University

**Perinatal Cannabidiol Exposure Decreases Survival in Mice, and Impacts Anxiety-like and Obsessive Compulsive-like Behavior and Object Memory in a Sexually Dimorphic Manner When Raised to Adult**

## CCORC 2022 Best Poster Presentation



### Amanda Pacheco-Spiewak

**Ph.D. Candidate**, Department of Pharmaceutics, University of Florida

**Preclinical Herb-Herb Interaction of Cannabidiol and Kratom in Rats**

---

## Recordings available to CCORC 2022 attendees

All CCORC 2022 attendees (both in-person and virtual) have access to recordings of all three keynote presentations as well as the event's closing awards ceremony.

If you are a CCORC 2022 attendee and wish to access these recordings, please contact [mmj.outcomes@cop.ufl.edu](mailto:mmj.outcomes@cop.ufl.edu)

## CLINICAL CORE UPDATES

### Medical Marijuana and Me (M<sup>3</sup>) Study


The Medical Marijuana & Me study is a longitudinal study of new and current medical marijuana patients in Florida. Since its launch in May, the study has enrolled 522 current medical marijuana patients and 61 new patients in Florida. Current patients completed a single, cross-sectional questionnaire while new patients completed the first of three questionnaires they will complete over 9 months.

### M<sup>3</sup> Participant Demographics (as of 7/20/22)

	Current Patients (Total: 522)	New Patients (Total: 61)
<b>Age, Mean (SD)</b>	46 (14)	46 (16)
<b>Sex at Birth</b>		
Female	63%	75%
Male	37%	25%
<b>Ethnicity</b>		
White	83%	80%
Black/African American	8%	15%
Other	9%	5%
Hispanic (% of Total)	15%	12%



## Map of M<sup>3</sup> Participants (as of 7/20/22)



**Interested in participating or learning more?**

Read about the study at [mmjoutcomes.org/JoinM3](https://mmjoutcomes.org/JoinM3)

**Are you a clinic or physician interested in supporting recruitment?**

Contact our study team at [m3cohort@phhp.ufl.edu](mailto:m3cohort@phhp.ufl.edu)

## OUTREACH UPDATES

Consortium members attended the Florida Medical Cannabis Conference and Exhibition in Orlando and the Annual Research Society on Marijuana Conference in Boston



The Consortium hosted a booth at the recent Florida Medical Cannabis Conference and Exhibition in Orlando, June 3-5. The conference, which has less of a research focus than our CCORC conference, helped the Consortium to connect with other researchers, clinicians, and industry professionals across the state.



The Consortium hosted a booth at the recent Florida Medical Cannabis Conference and Exhibition in Orlando, June 3-5. The conference, which has less of a research focus than our CCORC conference, helped the Consortium to connect with other researchers, clinicians, and industry professionals across the state. Conference in Boston, MA in July. RSMj highlighted the work of researchers, clinicians, and policy makers on both medical and non-medical marijuana use. The team also discussed the dose measure developed for the Medical Marijuana & Me Study during a poster session.

## GET INVOLVED IN RESEARCH

CARMMA: Changing the way we collaborate across the state of Florida

The [Connect and Advance Research for Medical Marijuana Analysis \(CARMMA\) Database](#) is accessible to researchers, physicians, and industry collaborators.

We believe collaborations bring research advancements. The CARMMA Database connects researchers, clinicians, and industry to foster medical marijuana research.

Anyone interested in engaging in medical marijuana research is invited to register in CARMMA to find collaborators.

**JOIN THE CARMMA DATABASE**

Have news or feedback to share?  
Let us know!

Share your Consortium-related research and news through our [submission form](#).

Share your comments on our newsletter through our [feedback form](#).

Don't want to miss any  
MEDICAMENT issues?

Share your contact information through our [newsletter sign-up form](#).

[Read previous MEDICAMENT issues on our website.](#)



Consortium for  
Medical Marijuana  
Clinical Outcomes Research